Skip to main
INAB
INAB logo

IN8BIO (INAB) Stock Forecast & Price Target

IN8BIO (INAB) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IN8bio Inc is exhibiting a positive outlook due to the encouraging efficacy results of its gamma-delta T cell product candidate, INB-100, particularly in preventing relapse in high-risk acute myeloid leukemia (AML) patients post-haploidentical stem cell transplantation, with a remarkable 100% overall survival rate at one year. The company’s ongoing study is expanding to include a multi-center 25-patient cohort, which is expected to further validate these results and enhance the product's market potential as enrollment is anticipated to complete by 2025. Additionally, INB-100 is demonstrating a favorable safety profile, with no reported treatment-related deaths or serious adverse events, underscoring its potential for further clinical advancement and commercial viability.

Bears say

The financial outlook for IN8bio reflects increased caution, as evidenced by the reduced 12-month price target from $8.00 to $6.00. Despite the potential shown by INB-619 in preclinical studies, the overall development pipeline may be hindered by challenges in transitioning candidates from preclinical to clinical stages. These factors raise concerns about the company's ability to effectively advance its gamma-delta T cell therapies in a competitive biopharmaceutical landscape.

IN8BIO (INAB) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IN8BIO (INAB) Forecast

Analysts have given IN8BIO (INAB) a Strong Buy based on their latest research and market trends.

According to 7 analysts, IN8BIO (INAB) has a Strong Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IN8BIO (INAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.